Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

de Weers, 2011, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, J Immunol, 186, 1840, 10.4049/jimmunol.1003032 Lammerts van Bueren, 2014, Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79, Blood, 124, 10.1182/blood.V124.21.3474.3474 Overdijk, 2015, Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, MAbs, 7, 311, 10.1080/19420862.2015.1007813 Overdijk, 2016, The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking, J Immunol, 197, 807, 10.4049/jimmunol.1501351 Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood, 128, 384, 10.1182/blood-2015-12-687749 Adams, 2019, High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action, Cytometry A, 95, 279, 10.1002/cyto.a.23693 Casneuf, 2021, Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab, Leukemia, 35, 573, 10.1038/s41375-020-0855-4 Kinder, 2021, Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma, Haematologica, 106, 2004, 10.3324/haematol.2020.268656 2022 Moreau, 2019, Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study, Lancet, 394, 29, 10.1016/S0140-6736(19)31240-1 Mateos, 2020, Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial, Lancet, 395, 132, 10.1016/S0140-6736(19)32956-3 Facon, 2019, Daratumumab plus lenalidomide and dexamethasone for untreated myeloma, N Engl J Med, 380, 2104, 10.1056/NEJMoa1817249 Mateos, 2020, Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR, Clin Lymphoma Myeloma Leuk, 20, 509, 10.1016/j.clml.2019.09.623 Bahlis, 2020, Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study, Leukemia, 34, 1875, 10.1038/s41375-020-0711-6 Dimopoulos, 2021, Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, Lancet Oncol, 22, 801, 10.1016/S1470-2045(21)00128-5 Chari, 2017, Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma, Blood, 130, 974, 10.1182/blood-2017-05-785246 Mateos, 2020, Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial, Lancet Haematol, 7, e370, 10.1016/S2352-3026(20)30070-3 San-Miguel, 2021, Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO), Haematologica, 106, 1725, 10.3324/haematol.2019.243790 Durie, 2006, International uniform response criteria for multiple myeloma, Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Terpos, 2022, Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: patient-reported outcomes from the APOLLO trial, Am J Hematol, 97, 481, 10.1002/ajh.26480 Dosne, 2023, Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma, Br J Clin Pharmacol, 89, 1640, 10.1111/bcp.15628 Richardson, 2021, Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM), Proc Am Soc Clin Oncol, 39 Richardson, 2022, Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, Lancet Oncol, 23, 416, 10.1016/S1470-2045(22)00019-5 Dimopoulos, 2023, Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial, J Clin Oncol, 41, 568, 10.1200/JCO.21.02815 Dimopoulos, 2023, Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial, J Clin Oncol, 41, 1590, 10.1200/JCO.22.00940 Sonneveld, 2023, Overall survival with daratumumab, bortezomib, and dexamethasone in previoulsy treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial, J Clin Oncol, 41, 1600, 10.1200/JCO.21.02734 Facon, 2021, Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, Lancet Oncol, 22, 1582, 10.1016/S1470-2045(21)00466-6 Yong, 2016, Multiple myeloma: patient outcomes in real-world practice, Br J Haematol, 175, 252, 10.1111/bjh.14213 Fonseca, 2020, Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma, BMC Cancer, 20, 10.1186/s12885-020-07503-y